Eilean Therapeutics
Clinical trials sponsored by Eilean Therapeutics, explained in plain language.
-
New drug ZE74-0282 targets rare blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests an experimental drug, ZE74-0282, in about 60 adults with polycythemia vera or myelofibrosis caused by a specific JAK2 gene mutation. The main goals are to find a safe dose and check for side effects, while also seeing if the drug shows signs of fighti…
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for advanced cancer patients? early trial of ZE94-0605 begins
Disease control Not yet recruitingThis early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC